DXC Technology

DXC Technology is a Fortune 500 global IT services and consulting company formed in 2017 through the merger of CSC (Computer Sciences Corporation) and HPE Enterprise Services. Headquartered in Virginia, DXC employs 125,000+ people across 70+ countries, providing technology services and solutions to enterprises worldwide.

The company operates a life sciences division that delivers full-stack capabilities across applications, data, AI, and infrastructure for pharmaceutical and biotechnology companies. DXC's life sciences offerings include DXC Tracker (regulatory information management), ClinicalWorks (pharmacovigilance technology), and broader IT infrastructure and application services tailored to regulated industries.

DXC Technology is a publicly traded company (NYSE: DXC) with reported Q4 FY2025 revenue of $3.17 billion, though down 6.4% year-over-year. CEO Raul Fernandez was appointed February 1, 2024. The company has undergone significant portfolio restructuring, including the sale of its healthcare software solutions division to Dedalus (Ardian portfolio company) and the finalization of a $5 billion spinoff of its health and human services business.

As a broad IT services company, DXC Technology serves multiple industries beyond life sciences, including banking, insurance, healthcare, manufacturing, and public sector. The life sciences division represents one segment of DXC's broader enterprise technology services portfolio, providing pharmaceutical companies with software solutions, cloud services, AI capabilities, and managed IT services.

DXC Technology is a broad IT services company serving multiple industries, with a dedicated life sciences division providing technology solutions to pharmaceutical and biotechnology companies. Life sciences represents one segment among many industries served by DXC, including banking, insurance, healthcare, manufacturing, and public sector.

The life sciences division offers full-stack capabilities across applications, data, AI, and infrastructure. DXC's pharmaceutical software portfolio includes DXC Tracker (regulatory information management for drug approvals and market authorization) and ClinicalWorks (pharmacovigilance technology). These solutions target pharmaceutical regulatory affairs and clinical safety workflows.

DXC states that it helps pharmaceutical customers "accelerate the journey of new drugs to market" through regulatory automation and compliance management. Specific pharmaceutical customer counts, named Big Pharma clients, and market-penetration metrics are undisclosed. DXC Tracker customer Quantum Regulatory Solutions achieved a 50% processing-time reduction, per a DXC case study.

DXC sold its healthcare software solutions division to Dedalus (Ardian portfolio company) and finalized a $5 billion spinoff of its health and human services business. Whether DXC Tracker and ClinicalWorks are part of the retained life sciences division, or were affected by the Dedalus transaction, is unstated. Beyond Quantum Regulatory Solutions, no additional pharmaceutical customer case studies are published. The lack of additional pharmaceutical case studies and the healthcare division sale indicate life sciences software is not a primary strategic focus for DXC Technology relative to its core IT infrastructure and consulting services.

DXC Technology is a publicly traded company (NYSE: DXC) and Fortune 500 enterprise. The company reported Q4 FY2025 revenue of $3.17 billion, down 6.4% year-over-year. The decline coincides with significant portfolio restructuring activity.

DXC has undergone substantial business transformation, including the sale of its healthcare software solutions division to Dedalus (an Ardian portfolio company) and the finalization of a $5 billion spinoff of its health and human services business. These divestitures reduce DXC's total addressable market in healthcare and life sciences while the company focuses on core IT services.

The company was formed in 2017 through the merger of CSC (Computer Sciences Corporation) and HPE Enterprise Services.

As a public company, DXC's financial performance is subject to quarterly earnings reports and SEC filings. DXC's long-term commitment to life sciences software, given the healthcare software division sale to Dedalus, is unstated.

DXC Technology's life sciences product portfolio centers on two pharmaceutical software solutions: DXC Tracker (regulatory information management) and ClinicalWorks (pharmacovigilance technology). These applications target specific pharmaceutical workflows including regulatory submissions, drug approval tracking, market authorization, and clinical safety management.

DXC Tracker is available on AWS Marketplace and incorporates AI-powered capabilities for automated document classification and multilingual document generation using Generative AI. The platform is part of DXC's broader RIM Platform that integrates regulatory compliance components for managing regulatory affairs content, data, and workflows. DXC Tracker is delivered as a managed service, combining software with DXC's professional services and ongoing platform management.

ClinicalWorks provides pharmacovigilance technology for clinical safety and adverse event management; further product detail is undisclosed.

Beyond these pharmaceutical-specific software products, DXC's life sciences division provides full-stack technology capabilities including cloud infrastructure services, AI/ML platforms, data analytics, and application modernization. These are general IT services adapted to life sciences rather than purpose-built pharmaceutical software.

DXC sold its healthcare software solutions division to Dedalus (Ardian portfolio company). Whether DXC Tracker and ClinicalWorks remain part of DXC's retained portfolio, or were transferred to Dedalus as part of the transaction, is unstated.

DXC Technology maintains partnerships with major cloud providers and enterprise technology vendors as part of its broader IT services business. DXC Tracker's availability on AWS Marketplace is a commercial relationship with Amazon Web Services, and the platform is deployed on AWS infrastructure.

As a large IT services company with 125,000+ employees, DXC likely maintains technology partnerships with Microsoft Azure, Google Cloud Platform, SAP, Oracle, Salesforce, and other enterprise software vendors. Partnership details specific to the life sciences division or pharmaceutical software products are undisclosed.

DXC provides services directly through its global delivery teams rather than through extensive third-party partner networks.

DXC Technology delivers DXC Tracker and other life sciences solutions as managed services, with ongoing support, platform management, and maintenance included as part of the service offering. The managed service model has DXC handling technical support, system administration, updates, and issue resolution on behalf of customers.

With 125,000+ employees across 70+ countries, DXC has global delivery capabilities for support services. Specific support availability — 24/7 coverage, regional support centers, supported languages — is undisclosed. As a Fortune 500 IT services company, DXC likely provides support SLAs and dedicated account teams for large pharmaceutical customers.

The life sciences division's full-stack capabilities across applications, data, AI, and infrastructure suggest comprehensive professional services including implementation, validation assistance, training, system integration, and consulting. Specific service offerings, pricing for professional services, training programs, customer success initiatives, and certification programs are undisclosed.

User community resources, annual customer conferences, online forums, knowledge bases, and self-service support portals are undisclosed. The managed service model may reduce the need for user communities, as DXC provides direct support rather than peer-to-peer knowledge sharing platforms.

DXC Technology is a Fortune 500 company and publicly traded enterprise (NYSE: DXC). The company was formed in 2017 through the merger of two major technology services firms, CSC (Computer Sciences Corporation) and HPE Enterprise Services.

CEO Raul Fernandez was appointed February 1, 2024. Leadership team and organizational structure beyond the CEO are undisclosed; as a Fortune 500 company with 125,000+ employees, DXC maintains corporate governance and executive oversight typical of large public enterprises.

DXC publishes a corporate certifications register and states that its service offerings are certified under ISO/IEC 27001, SOC 1 and SOC 2, alongside ISO 22301, ISO 27701, ISO 27017/27018, ISO 45001, ISO 50001 and ISO 13485, with roughly 350 sites across 50 countries certified to one or more. Which of those certifications cover the life sciences division or the specific products profiled here is unstated — the register is site- and service-scoped and names no product.

There is no Gartner, Forrester, or other analyst recognition documented for the life sciences division. No awards, whitepapers, webinars, industry presentations, or other indicators of pharmaceutical-industry reputation specific to pharmaceutical software are published.

DXC sold its healthcare software solutions division to Dedalus and finalized a $5 billion spinoff of its health and human services business; Q4 FY2025 revenue declined 6.4% year-over-year. DXC's strategic commitment to life sciences software and its long-term product roadmap for pharmaceutical customers are unstated.

DXC Technology maintains a corporate web presence at dxc.com with dedicated pages for life sciences industry solutions. Visibility specifically within pharmaceutical quality management and regulatory software markets is unstated.

DXC Tracker is available on AWS Marketplace. No G2, Capterra, or Gartner Peer Insights listing for DXC Tracker is documented.

Whitepapers, case studies, demo videos, webinars, and other thought-leadership content specific to pharmaceutical software are undisclosed beyond a Quantum Regulatory Solutions case study, in which DXC Tracker is credited with a 50% processing-time reduction. Broader content-marketing activity specific to pharmaceutical software is undisclosed.

Press-release frequency, recent news coverage, social-media activity, and digital-marketing presence specific to the life sciences division are undisclosed. DXC issues quarterly earnings reports and corporate press releases as a public company; none identified are specific to pharmaceutical software.

DXC sold its healthcare software solutions division to Dedalus, indicating reduced investment in healthcare and life sciences software products; the divestiture may affect market perception of DXC's long-term commitment to pharmaceutical customers and its product-innovation roadmap for life sciences.